This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • BeiGene announces positive topline results for glo...

BeiGene announces positive topline results for global phase III trial of tislelizumab in esophageal squamous cell carcinoma.

Read time: 1 mins
Published:29th Jan 2021
BeiGene, Ltd. announced that the global Phase III RATIONALE 302 trial of its anti-PD-1 antibody tislelizumab versus investigator’s choice chemotherapy in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior systemic treatment met its primary endpoint of overall survival (OS) In the trial results, tislelizumab demonstrated a statistically significant and clinically meaningful improvement in OS in the intention-to-treat (ITT) population, when compared to chemotherapy. The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified. BeiGene plans to discuss the RATIONALE 302 data with health authorities globally and present data at an upcoming medical conference..
Condition: Oesophageal Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.